Calculated benefit of risk reduction surgery


Long-Term Benefits of Bilateral Salpingo-Oophorectomy

Study Reference: Prospective Cohort Study; JAMA Surgery (2026)

Many women with a family history of ovarian cancer or a confirmed BRCA1 or BRCA2 pathogenic variant elect to undergo risk-reducing surgery to manage their lifetime cancer risk. Looking at calculated outcomes from a large prospective cohort of 5,713 women, this study measures the protective benefits of bilateral salpingo-oophorectomy (BSO). The findings demonstrate substantial reductions in both ovarian cancer incidence and overall mortality; this evidence provides clear guidance for clinicians and women navigating prophylactic surgical decisions.

Key Points

  • Substantial Risk Reduction: Bilateral salpingo-oophorectomy lowers the risk of ovarian, fallopian tube, and primary peritoneal cancers by approximately 80%.

  • Overall Survival Advantage: Prophylactic surgery significantly reduces all-cause mortality among women carrying BRCA pathogenic variants.

  • Critical Importance of Timing: Surgical timing remains paramount; BSO offers optimal protective benefits when performed within recommended age windows (typically ages 35–40 for BRCA1 and 40–45 for BRCA2).

  • Cohort Scale: Data across the cohort of 5,713 women confirm that deferring surgery past age 50 sharply increases residual ovarian cancer risk.

What This Means for Ovarian Cancer Support Nurses

  • Prophylactic Benefit: Reassure callers with BRCA mutations that risk-reducing salpingo-oophorectomy provides proven, dramatic reductions in ovarian cancer risk and long-term mortality.

  • Surgical Timing: Guide callers to discuss optimal age windows with their Familial Cancer Centre or specialist team; this ensures surgical decisions account for their specific gene mutation (BRCA1 vs BRCA2).

  • Shared Decision-Making: Provide women evaluating prophylactic surgery with clear, evidence-based figures; this helps alleviate anxiety surrounding complex preventive choices.

Tags: #OvarianCancer #BRCA1 #BRCA2 #RiskReducingSurgery #PreventativeMedicine #SurvivorshipCare #SupportNursing

Comments

Post a Comment

Popular posts from this blog

An impossible dream?

Image
Reducing ovarian cancer mortality through screening: an impossible dream? https://tinyurl.com/4524jh8f The history of screening tests for ovarian cancer is not good. Two huge trials; the UKCTOCS with  more than 200,000 recruits over 20 years and the PLCO trial with more than 3 million pathology samples  sho wed no benefit in terms of survival from ovarian cancer. This article addresses the stages of ovarian cancer using  an alternative approach called the clinical continuum,  which divides cancer into 3 phases ,  no disease, pre-clinical  (detectable disease) , and  clinical (overt cancer). Obviously for a screening test to be effective ,   cancer needs to be detected before the clinical  phase. However, ovarian cancer is unlike other cancer in that the precursor occurs in the fallopian tube and the re is an argument to say that ,  by the time ovarian cancer has occurred ,  it is always advanced and metastatic .   T his time in...
Read more

Sugar doesn’t feed cancer

Image
Revisiting the Warburg-Based “Sugar Feeds Cancer” Hypothesis: A Critical Appraisal of Epidemiological, Experimental and Mechanistic Evidence https://tinyurl.com/3v2tysdt Many clinical care professionals receive queries from cancer patients about whether they should modify their diet to red u ce consumed sugar. This concern is based on a misunde r standing of some basic medical research known as the Warbur g effect. Research from 1956 show ed that cancer cells alter their metaboli sm to enable increased glucose uptake and increase energy production. A misunderstanding of this effect has led to incorrect dietary advice to cancer patients suggesting sugar restriction may be benefi cial. As a result, malnutrition , which is already a s i gnificant cause of morbidity for cancer patients , can be exacerbated . No hard evidence that low sugar diets alter survival exists. Some anecdotal reports suggest a slight correlation with risk. This study is a n appraisal of all credible re...
Read more

All about theranostics

Image
Australian ovarian cancer breakthrough enters human trials https://tinyurl.com/ye245f8f Medicine is full of new words or neologisms. Mostly thes e are produced by PR agencies looking for a memorable brand name for a new drug. Sometimes the new name marks a dramatic shift in medical care. One such is theranostic s a complex noun first used in 1997 to name a marriage of therapy and diagnosis. Theranostics are combinations of antibodies and radiopha rmaceuticals currently being used in the treatment o f prostate cancer and carcinoid. The radi o pharmace utical of choice is lutetium-177 which is a n isotope with a short half-life and an intense Beta emitter. Beta radiation is of high energy with low penetration and highly toxic, Standard systemic brachytherapy with Beta emitters is likely to kill the patient before killing the cancer . The antibody combination targets the radiation to the cancer cell meaning only a low non-fatal dose is required . The antibody is produced ...
Read more